Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Seagen Inc

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
3 Steal-of-a-Deal Stocks to Snap Up Right Now
Here are three steal-of-a-deal stocks that offer meaningful upside for investors looking for stocks that are on sale now. 
Via InvestorPlace
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Get Rich Quick with These 7 Growth Stocks to Buy Now
Here are seven growth stocks to buy that will let you know by their price action if the current bull market is ready to expand. 
Via InvestorPlace
7 Dividend Stocks to Buy at a 52-Week Low
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround. 
Via InvestorPlace
Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market
Pfizer is in Wall Street's doghouse, but don't despair. At its current price, value seekers ought to relish the opportunity to buy PFE stock. 
Via InvestorPlace
Looking Into Seagen's Recent Short Interest
Via Benzinga
What the Options Market Tells Us About Seagen
Via Benzinga
$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today
Via Benzinga
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations. 
Via InvestorPlace
How To Earn $500 A Month From Pfizer Stock
Pfizer Inc. (NYSE: PFE) shares closed almost flat on Friday, but lost around 44% during 2023. 
Via Benzinga
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
3 Stocks That Are About to Get Absolutely Crushed
These are a few different companies that are experiencing difficult times and that are expected to keep falling. 
Via InvestorPlace
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 Today
Via Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years
Via Benzinga
Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. (NYSE: PFE),  
Via Benzinga
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen. 
Via The Motley Fool
3 Sleepy Stocks Ready to Wake up in 2024
Strong projected earnings growth makes these three stocks strong candidates for exceptional growth in 2024. 
Via InvestorPlace
Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Shake Shack Inc (NYSE: SHAK) 
Via Benzinga
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints
Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target. 
Via Investor's Business Daily
Why Is US Pharma Giant Pfizer Stock Trading Lower Today?
Pfizer Inc (NYSE: PFE) provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen Inc (NASDAQ: SGEN) transaction. 
Via Benzinga
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition
Pfizer Inc (NYSE: PFE)  
Via Benzinga
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)  
Via Benzinga
3 Blue-Chip Stocks Set to Make a Comeback in 2024
These are the blue-chip stocks to buy as they represent quality companies with a steady growth outlook and promising cash flow growth. 
Via InvestorPlace
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love
Buying stocks simple for their high dividend yields is risky but these are three stocks the elite love regardless. 
Via InvestorPlace
The 7 Most Undervalued Sleeper Stocks to Buy Now: November 2023
Here are just a few of the most undervalued sleeper stocks investors may want to consider heading into the new year. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BioNTech Stock Surges On Surprise Profit, Strong Sales. But Report Has Downside.
The company was expected to report a third-quarter loss and plummeting sales. 
Via Investor's Business Daily
This Is The 'Only Solar Stock' Jim Cramer Is Recommending 'Because It's A Pure Play'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said DocuSign, Inc. 
Via Benzinga
CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross’ Tongue
Bill Gross, the Bond King, is wading into the world of equity arbitrage with these three stocks - but are they worth the risk for investors? 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.